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A population-based series of 649 unselected incident cases of ovarian cancer diagnosed in Ontario, Canada, during
1995–96 was screened for germline mutations in BRCA1 and BRCA2. We specifically tested for 11 of the most
commonly reported mutations in the two genes. Then, cases were assessed with the protein-truncation test (PTT)
for exon 11 of BRCA1, with denaturing gradient gel electrophoresis for the remainder of BRCA1, and with PTT
for exons 10 and 11 of BRCA2. No mutations were found in all 134 women with tumors of borderline histology.
Among the 515 women with invasive cancers, we identified 60 mutations, 39 in BRCA1 and 21 in BRCA2. The
total mutation frequency among women with invasive cancers, 11.7% (95% confidence interval [95%CI]
9.2%–14.8%), is higher than previous estimates. Hereditary ovarian cancers diagnosed at age !50 years were mostly
(83%) due to BRCA1, whereas the majority (60%) of those diagnosed at age 160 years were due to BRCA2.
Mutations were found in 19% of women reporting first-degree relatives with breast or ovarian cancer and in 6.5%
of women with no affected first-degree relatives. Risks of ovarian, breast, and stomach cancers and leukemias/
lymphomas were increased nine-, five-, six- and threefold, respectively, among first-degree relatives of cases carrying
BRCA1 mutations, compared with relatives of noncarriers, and risk of colorectal cancer was increased threefold
for relatives of cases carrying BRCA2 mutations. For carriers of BRCA1 mutations, the estimated penetrance by
age 80 years was 36% for ovarian cancer and 68% for breast cancer. In breast-cancer risk for first-degree relatives,
there was a strong trend according to mutation location along the coding sequence of BRCA1, with little evidence
of increased risk for mutations in the 5′ fifth, but 8.8-fold increased risk for mutations in the 3′ fifth (95%CI
3.6–22.0), corresponding to a carrier penetrance of essentially 100%. Ovarian, colorectal, stomach, pancreatic,
and prostate cancer occurred among first-degree relatives of carriers of BRCA2 mutations only when mutations
were in the ovarian cancer–cluster region (OCCR) of exon 11, whereas an excess of breast cancer was seen when
mutations were outside the OCCR. For cancers of all sites combined, the estimated penetrance of BRCA2 mutations
was greater for males than for females, 53% versus 38%. Past studies may have underestimated the contribution
of BRCA2 to ovarian cancer, because mutations in this gene cause predominantly late-onset cancer, and previous
work has focused more on early-onset disease. If confirmed in future studies, the trend in breast-cancer penetrance,
according to mutation location along the BRCA1 coding sequence, may have significant impact on treatment
decisions for carriers of BRCA1-mutations. As well, BRCA2 mutations may prove to be a greater cause of cancer
in male carriers than previously has been thought.
Introduction
Germline mutations in BRCA1 (MIM 113705) and
BRCA2 (MIM 600185) account for cancer predisposi-
tion in the majority of families with the breast ovarian-
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cancer syndrome (Narod et al. 1995; Frank et al. 1998).
The probability of finding a mutation in a woman with
ovarian cancer increases with the number of related cases
of ovarian or early-onset breast cancer in her family. It
is not yet clear what proportions of ovarian cancer in
unselected general populations are due to mutations in
these genes. Some estimates have been made for BRCA1
(Matsushima et al. 1995; Takahashi et al. 1995; Stratton
et al. 1997; Rubin et al. 1998; Janezic et al. 1999), but
the fraction attributable to BRCA2 is less well known
(Foster et al. 1996; Takahashi et al. 1996; Khoo et al.
2000; Van der Looij et al. 2000). Furthermore, previous
studies have been limited by small sample sizes and by
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potentially unrepresentative case sampling through the
use of early-onset, hospital-based, prevalent or self-re-
ferred cases.
Accurate knowledge of the proportion of cases car-
rying mutations in these genes is important in order to
offer genetic screening and counseling to women with
either ovarian cancer or family histories of cancer. It is
not yet known whether cases of ovarian cancer asso-
ciated with BRCA2 mutations differ from those asso-
ciated with BRCA1 mutations, in terms of age at di-
agnosis or of histological type, for example. To address
these questions, we studied 649 unselected incident
cases of ovarian cancer in Ontario and examined the
presence of mutations with respect to age, histology,
ethnicity, and family history.
Subjects and Methods
Subjects
All patients in the province of Ontario who had been
diagnosed with epithelial ovarian tumors, from January
1995 through December 1996, were identified by mon-
itoring of acquisitions at the Ontario Cancer Registry.
For each case, the investigators reviewed pathology re-
ports to determine eligibility and histological type. Pa-
tients were 20–79 years of age and were resident in On-
tario at the time of diagnosis of a new primary borderline
or invasive epithelial ovarian tumor. Of 1,024 eligible
cases, we were able to obtain and test blood samples
from 649 (63%). The reasons for nonparticipation of
the other 375 cases included death (197 cases), subject
refusal (76 cases), severity of illness (57 cases), physician
refusal (5 cases), and inability to be found (8 cases).
Family histories were taken by telephone interview. Sty-
rofoam-packed venipuncture kits with consent forms
were mailed to subjects, who had blood samples drawn
locally and, along with signed consent forms, returned
by prepaid courier. All participants were offered the op-
tion of receiving their genetic-testing results, in the con-
text of a counseling clinic, via either the study team or
counseling clinics elsewhere in the province. The study
was approved by the institutional review boards of the
University of Toronto and Yale University.
BRCA1 and BRCA2 Analysis
Lymphocyte DNA was prepared from whole blood by
standard procedures. All samples were screened for 11
common mutations (seven in BRCA1 and four in
BRCA2). Included were the three mutations common to
Ashkenazi Jews and others of eastern-European extrac-
tion, as well as the six mutations that previously had
been identified in the French Canadian population
(Tonin et al. 1998). These founder mutations were as-
sayed by a rapid multiplex method (Kuperstein et al.
2000). We separately tested for the presence of the
BRCA1 exon 13 6-kb duplication (Puget et al. 1999)
and for the BRCA1 exon 7 mutation, G546T.
Exon 11 of BRCA1 and exons 10 and 11 of BRCA2
were then screened by the protein-truncation test (PTT).
Primer sequences used to amplify overlapping fragments
were obtained from the Breast Cancer Information Core
(BIC). PTT was performed by the TNT rabbit retic-
ulocyte lysate system (Promega), with [35S]-methionine/
cysteine (New England Nuclear) being incorporated for
protein detection.
Cases that, by the previous testing, had been found
not to carry mutations were then screened for additional
BRCA1 mutations, by fluorescent multiplex denaturing
gradient gel electrophoresis (DGGE) (G.K., E.J., H.A.R.,
J.R.M., and S.A.N., unpublished data). All of the re-
maining coding exons, the exon-intron boundaries, and
the beginning and end of exon 11 were included; non-
coding exon 1a and 1b and the noncoding part of exon
24 were excluded.
In all cases, variants identified by PTT and DGGE
were confirmed by direct DNA sequencing (Promega).
We believe that all of the observed mutations are dele-
terious. The various founder mutations are known to be
deleterious, and PTT identifies mutations associated
with shortened, nonfunctional proteins. The specificmu-
tations found by DGGE have all been seen previously
and, as documented in the Breast Cancer Information
Core (BIC) database, are known to be deleterious.
Statistical Analysis
Confidence limits for mutation frequencies were cal-
culated under the assumption of binomial distributions
of the observed numbers of cases. Relative risks (RRs)
of cancer in family members, according to BRCA1 and
BRCA2mutation status of the proband, were calculated
through proportional-hazards regression, with the base-
line taken to be relatives of cases not carryingmutations.
Each family member was assumed to be at risk until
either diagnosis of the cancer of interest, death, or age
at the time when the family history was reported. Cu-
mulative incidence of cancer among relatives was ob-
tained by calculating the estimated survival function to
age 80 years, from the regression models, and then sub-
tracting it from unity. Penetrance estimates for carriers
of mutations were calculated by the method of Wach-
older et al. (1998).
Results
Among the 515 women in our study who had invasive
cancers, 60 mutations (11.7% [95% confidence interval
[95%CI] 9.2%–14.8%) were identified, including 39
mutations in BRCA1 and 21 in BRCA2 (table 1). No
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Table 1
BRCA1 and BRCA2 Mutations Detected in 649 Women with
Ovarian Cancer
Gene and Ethnicity (Age of Patient)a Region Mutation
BRCA1:
Ashkenazi Jewish (37 years) Exon 2 185delAG
Ashkenazi Jewish (41 years) Exon 2 185delAG
Indo-Pakistani (46 years) Exon 2 185delAG
Ashkenazi Jewish (59 years) Exon 2 185delAG
Ashkenazi Jewish (66 years) Exon 2 185delAG
British Isles (49 years) Intron 4 IVS41 GrT
Slavic (45 years) Exon 5 T300G
Mixed European (50 years) Exon 5 T300G
Slavic (42 years) Exon 11 962del4
Mixed European (65 years) Exon 11 962del4
French Canadian (50 years) Exon 11 G1081A
Mixed European (52 years) Exon 11 G1081A
British Isles (60 years) Exon 11 1294del40
Italian (43 years) Exon 11 1479delAG
Italian (62 years) Exon 11 1479delAG
Indo-Pakistani (49 years) Exon 11 1768delA
Mixed European (47 years) Exon 11 2080delA
British Isles (48 years) Exon 11 2190delA
Mixed European (55 years) Exon 11 2524delTG
French Canadian (52 years) Exon 11 2800delAA
British Isles (42 years) Exon 11 2819delTT
French Canadian (39 years) Exon 11 2953delGTA/insC
Mixed European (78 years) Exon 11 T3053G
British Isles (54 years) Exon 11 3375insGA
French Canadian (53 years) Exon 11 3768insA
Slavic (42 years) Exon 11 3819delGTAAA
Italian (39 years) Exon 11 3875delGTCT
Italian (57 years) Exon 11 3875delGTCT
British Isles (46 years) Exon 11 3879insT
Italian (71 years) Exon 12 G4236T
British Isles (46 years) Exon 13 6-kb duplication
Mixed European (46 years) Exon 13 6-kb duplication
British Isles (49 years) Exon 13 6-kb duplication
French Canadian (47 years) Exon 13 C4446T
Mixed European (48 years) Intron 16 IVS166 TrG
Mixed European (53 years) Exon 20 C5370T
Slavic (46 years) Exon 20 5382insC
Greek (50 years) Exon 20 5382insC
Mixed European (72 years) Exon 20 5382insC
BRCA2:
Mixed European (45 years) Exon 10 1257delA
Mixed European (51 years) Exon 11 2814del7
British Isles (67 years) Exon 11 3908delTG
British Isles (72 years) Exon 11 4075delGT
Italian (62 years) Exon 11 4510insT
British Isles (62 years) Exon 11 4706del4
Philippines (49 years) Exon 11 4859delA
British Isles (71 years) Exon 11 T5087G
Mixed European (51 years) Exon 11 5102delAA
British Isles (73 years) Exon 11 5102delAA
Italian (65 years) Exon 11 5302insA
British Isles (56 years) Exon 11 C5910G
Mixed European (44 years) Exon 11 6174delT
Ashkenazi Jewish (53 years) Exon 11 6174delT
Mixed European (66 years) Exon 11 6181delTC
British Isles (57 years) Exon 11 6503delTT
Mixed European (51 years) Exon 11 6602insA
Japanese (65 years) Exon 11 6633del5 (delCTTAA)
Mixed European (60 years) Exon 11 6872del4 (delACTC)
French Canadian (48 years) Exon 20 8765delAG
Mixed European (40 years) Exon 27 9894delT
a All ethnicities are non-Jewish, except as indicated.
mutations were seen in the 134 women with borderline
tumors. All 60 women carrying mutations were unre-
lated. Of the 39 cases having BRCA1mutations, 11were
identified in the screens for individual mutations, 20
were identified by PTT of exon 11, and 8 were identified
by DGGE. We observed 26 distinct BRCA1 mutations,
including 8 that were identified more than once. Two
intronic mutations (IVS41 GrT and IVS166 TrG)
were found.
In our case series, five women carried the BRCA1
185delAGmutation and three carried the 5382insCmu-
tation. One of the five women with the 185delAG mu-
tation was non-Jewish, of Pakistani ancestry. None of
the three women with the 5382insC mutation reported
being Jewish or were known to be Jewish. We also iden-
tified three women with the exon 13 6-kb duplication
mutation. All three women had either complete or par-
tial British Isles ancestry. Interestingly, we identified two
women of Italian ethnicity who had the apparently
novel 1479delAG mutation.
In the testing for BRCA2, 19 of the 21 mutations were
identified by PTT. One founder mutation (8765delAG)
was observed, in a French Canadian woman. Nineteen
of the 21 BRCA2 mutations were unique. Two women
with either British Isles or European ancestry carried
5102delAA mutations. The 6174delT mutation was also
seen in two cases, one of whom was Jewish. Only 13 of
the 21 BRCA2 mutations occurred within the ovarian
cancer–cluster region (OCCR; most recently defined as
nucleotides 4075–6503 inclusive) of exon 11 (Thompson
and Easton 2001).
Frequency of mutations, by ethnic group, is shown
in table 2. High mutation frequency among these ovar-
ian-cancer cases was seen for women of Jewish (26%),
Italian (24%), and Indo-Pakistani (14%) ancestry. Total
mutation frequency for women of British Isles ancestry
was 4.7%:2.5% for BRCA1 mutations and 2.2% for
BRCA2 mutations.
The presence of a mutation could be predicted, to
some degree, on the basis of age at diagnosis, histolog-
ical subtype, and family history. Age at diagnosis related
both to the presence of a mutation and to the particular
gene involved (table 3). Women diagnosed at age 40–50
years had the highest frequency of mutations (18.4%),
which was more than double that of women whose age
at diagnosis was outside this range (6.8%); women with
cancer at age !40 years had a lower prevalence of mu-
tations (4.2%).
There were marked differences between the age dis-
tribution of the cases with BRCA1 mutations and that
of cases with BRCA2 mutations. The average age at
diagnosis of the BRCA1-positive cases was 51.2 years,
which was less than the age at diagnosis of the cases in
whom mutations were not detected (55.6 years; Pp
); the average age at diagnosis of the 21 cases with.041
Risch et al.: BRCA1 and BRCA2 Mutations in Ovarian Cancer 703
Table 2
Frequency of Mutations in Cases of Ovarian Cancer, by Ethnicity
ETHNICITY
NO. (%) POSITIVE
FOR MUTATIONS IN
BRCA1 BRCA2 Either
French Canadian ( )np 60 5 (8.3) 1 (1.7) 6 (10.0)
Ashkenazi Jewish ( )np 19 4 (21.1) 1 (5.3) 5 (26.3)
Indo-Pakistani ( )np 14 2 (14.3) 0 (0) 2 (14.3)
Chinese, Japanese, etc. ( )np 19 0 (0) 1 (5.3) 1 (5.3)
Italian ( )np 29 5 (17.2) 2 (6.9) 7 (24.1)
Hispanic ( )np 17 0 (0) 0 (0) 0 (0)
British Isles ( )np 316 8 (2.5) 7 (2.2) 15 (4.7)
Mixed European ( )np 142 10 (7.0) 8 (5.6) 18 (12.7)
Table 3
Frequency of Mutations in Cases of Ovarian Cancer, by
Age at Diagnosis
AGE GROUP
NO. (%) POSITIVE
FOR MUTATIONS IN
BRCA1 BRCA2 Either
40 years ( )np 96 3 (3.1) 1 (1.0) 4 (4.2)
4150 years ( )np 136 21 (15.4) 4 (2.9) 25 (18.4)
5160 years ( )np 165 9 (5.5) 7 (4.2) 16 (9.7)
160 years ( )np 252 6 (2.4) 9 (3.6) 15 (6.0)
All ( )np 649 39 (6.0) 21 (3.2) 60 (9.2)
BRCA2 mutations was 57.5 years, which was similar
to the average age at diagnosis of other invasive-cancer
cases in whom mutations were not identified (57.8
years). The majority (9/15) of mutations in women di-
agnosed with ovarian cancer at age 160 years were in
BRCA2; in contrast, 24 of 29 mutations in women of
age !50 years were in BRCA1.
All women with borderline or invasive cancers di-
agnosed in Ontario were eligible for inclusion in our
study. Of the total of 649 cases, 134 (20.6%) had bor-
derline tumors. As we have said, none of these women
carried a mutation (table 4). Fifty-six (93%) of the 60
subjects with mutations had invasive serous cancers
(this subgroup represents 53% of the total cases), and
women with these cancers were almost twice as likely
to carry BRCA1 mutations as to carry BRCA2 muta-
tions. In addition, four women with endometrioid tu-
mors were found to be carriers of mutations, and no
woman with a mucinous tumor was found to be a
carrier.
Family history also predicted the presence of a mu-
tation (table 5). Women with first-degree relatives af-
fected by breast or ovarian cancer had a mutation fre-
quency of 19% (27/144). Mutations were also observed
in 33 (6.5%) of 505 women who reported no first-
degree relatives with breast or ovarian cancer. Using a
definition of “potential familiality” to denote the pres-
ence of either (a) a first-degree relative either with ovar-
ian cancer or with breast cancer at age !60 years or (b)
a combination of two or more first- or second-degree
relatives with breast or ovarian cancer, we found that
26% of such cases carry mutations. Women with both
invasive serous cancers and potential familiality had the
highest frequency of mutation, 36% (36/99). Twenty-
eight (72%) of 39 women with BRCA1 mutations had
both invasive serous tumors and potential familiality,
compared with 8 (38%) of 21 with BRCA2 mutations
( ).Pp .011
We estimated the cumulative incidence, by age 80
years, of various types of cancer among first-degree rel-
atives of the women with ovarian cancer, according to
the carriage of either BRCA1 mutation or BRCA2 mu-
tation by the proband case (table 6). Compared with
relatives of noncarriers, the RR for ovarian cancer
among female relatives of carriers of BRCA1mutations
was 8.6 (95%CI 4.1–18). This elevated risk did not
differ significantly between mothers (RR 8.6 [95%CI
3.3–23]) and sisters (RR 7.1 [95%CI 2.3–22]). In total,
19% of female first-degree relatives of carriers of
BRCA1 mutations were estimated to be diagnosed with
ovarian cancer by age 80 years, which gives a 36%
lifetime penetrance for carriers.
A significant increase in risk of breast cancer in rel-
atives of carriers of BRCA1 mutations was also found
(RR 4.8 [95%CI 3.0–7.6]), and this too was not sig-
nificantly different between mothers (RR 3.5 [95%CI
1.7–7.2]) and sisters (RR 5.3 [95%CI 2.6–11]). In total,
39% of female first-degree relatives of carriers of
BRCA1 mutations got breast cancer by age 80 years,
for an estimated carrier penetrance of 68%. As well,
we observed significantly increased risks of stomach
cancer and leukemias/lymphomas among relatives of
carriers of BRCA1 mutations (RR 6.2 [95%CI
2.0–19.0] and RR 2.6 [95%CI 1.02–6.6], respectively)
and, among female first-degree relatives, increased risks
for all cancer sites combined (RR 3.6 [95%CI 2.5–5.0]).
The estimated penetrance by age 80 years, of cancer of
any type among female carriers of BRCA1 mutations,
is thus nearly 100%.
A lesser increase in risk of ovarian cancer was ob-
served among relatives of carriers of BRCA2mutations
(RR 2.5 [95%CI 0.59–11]), and this also did not seem
to differ between mothers and sisters. We did not find
an excess of breast cancer among relatives of carriers
of BRCA2mutations, with only 4 cases reported among
79 female first-degree relatives. However, significantly
increased risk was seen for colorectal cancer (RR 2.5
[95%CI 1.02–6.3]), corresponding to a carrier lifetime-
penetrance estimate of 16%. In addition, for all cancer
sites combined, increased risk was observed amongmale
first-degree relatives (RR 1.7 [95%CI 0.97–3.1]), for a
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Table 4
Frequency of Mutations in Cases of Ovarian Cancer, by
Histology
HISTOLOGY
NO. (%) POSITIVE
FOR MUTATIONS IN
BRCA1 BRCA2 Either
Invasive ( )np 515 39 (7.6) 21 (4.1) 60 (11.7)
Serous ( )np 341 37 (10.9) 19 (5.6) 56 (16.4)
Endometrioid ( )np 94 2 (2.1) 2 (2.1) 4 (4.3)
Mucinous ( )np 44 0 (0) 0 (0) 0 (0)
Other ( )np 36 0 (0) 0 (0) 0 (0)
Borderline ( )np 134 0 (0) 0 (0) 0 (0)
Table 5
Frequency of Mutations in Cases of Ovarian Cancer, by Family History of Breast or Ovarian Cancer
FAMILY HISTORY
NO. (%) POSITIVE
FOR MUTATIONS IN
BRCA1 BRCA2 Either
Mother with:
Breast cancer ( )np 58 9 (15.5) 1 (1.7) 10 (17.2)
Ovarian cancer ( )np 20 6 (30.0) 1 (5.0) 7 (35.0)
Sister with:
Breast cancer ( )np 52 5 (9.6) 3 (5.8) 8 (15.4)
Ovarian cancer ( )np 17 4 (23.5) 1 (5.9) 5 (29.4)
Any first-degree relative with breast or ovarian cancer ( )np 144 21 (14.6) 6 (4.2) 27 (18.7)
Proband with:
Previous breast cancer ( )np 30 9 (30.0) 1 (3.3) 10 (33.3)
Potential familiality:a
All case histologies ( )np 145 29 (20.0) 9 (6.2) 38 (26.2)
Invasive serous cases only ( )np 99 28 (28.3) 8 (8.1) 36 (36.4)
No potential familiality ( )np 504 10 (2.0) 12 (2.4) 22 (4.4)
a Defined as having either (a) a first-degree relative either with ovarian cancer or with breast cancer at
age !60 years or (b) a combination of two or more first- or second-degree relatives with breast cancer or
ovarian cancer.
carrier lifetime penetrance of 53%, which is appreciably
greater than the 38% calculated for females.
Finally, we were able to examine cancer risk in first-
degree relatives according to location of the BRCA1 or
BRCA2mutation within the coding sequence of the gene.
For this analysis, we assumed the “location” of the
BRCA1 exon 13 6-kb duplication to be at nucleotide
4497, since it results in an abnormal ter1460 in the
mRNA (Puget et al. 1999). For BRCA1, we found a
strong trend for risk of breast cancer in family members
to increase with more-downstream location of the mu-
tation (continuous trend ; a 26% increase inPp .0014
risk with each additional 10% [p559 nucleotides] of
downstream distance). There was little evidence to sug-
gest that mutations in the 5′ fifth of the BRCA1 coding
sequence (nucleotides 120–1237) were associated with
increased breast-cancer risk (RR 1.3 [95%CI 0.33–5.5]).
Mutations in subsequent fifths, however, were increas-
ingly so associated: RR 1.6 (95%CI 0.22–11) for mu-
tations in nucleotides 1238–2355, RR 7.4 (95%CI
3.0–18) within nucleotides 2356–3474, RR 7.2 (95%CI
3.6–14) in nucleotides 3475–4592, and RR 8.8 (95%CI
3.6–22) in nucleotides 4593–5711. These RRs corre-
spond to carrier penetrance estimates, by age 80 years,
of 16%, 21%, 97%, 96%, and 100% for mutations in
the successive fifths of BRCA1. Although, as noted
above, we observed little elevation in risk of breast cancer
in family members of cases with BRCA2 mutations in
general, we did see an increased risk associated with mu-
tations outside the OCCR (RR 4.2 [95%CI 1.5–11]).
This increase was essentially due to mutations occurring
distal to the OCCR (RR 4.7 [95%CI 1.5–15]).
For ovarian cancer in first-degree relatives, we ob-
served no differences in risk according to location of
the BRCA1 mutation. In BRCA2, ovarian cancers oc-
curred among family members of cases carrying mu-
tations only when the mutations were within the
OCCR. For OCCR mutations, the RR was 3.6 (95%CI
0.85–15), which is of borderline statistical significance
( ).Pp .08
We also examined mutation location with respect to
colorectal, stomach, pancreatic, and prostate cancer in
family members. There were no associations with lo-
cation of BRCA1 mutations. However, for probands
carrying BRCA2 mutations, colorectal cancer in family
members occurred only when mutations were within
the OCCR (RR 3.4 [95%CI 1.4–8.5]); stomach, pan-
creatic, and prostate cancers in family members also
occurred for BRCA2mutations only within the OCCR.
The RR of ovarian, colorectal, stomach, pancreatic, or
prostate cancer in family members, for OCCR BRCA2
mutations, was 3.1 (95%CI 1.7–5.7; ). ThisPp .0003
specificity for OCCR mutations also accounted for the
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Table 6
Cumulative Incidence and Relative Risk of Cancer among First-Degree Relatives, by Proband Mutation Status and Cancer
Site
SITE
CUMULATIVE INCIDENCE OF CANCER, BY AGE 80 YEARS, IN RELATIVES OF CASES WITHa
No Mutations BRCA1 Mutations BRCA2 Mutationsb
Incidence
(%) RR
Incidence
(%) RR (95%CI)
Incidence
(%) RR (95%CI)
Ovary 2.5 1.0 19.4 8.6 (4.1–18) 6.1 2.5 (.59–11)
Breast 9.9 1.0 39.1 4.8 (3.0–7.6) 11.9 1.2 (.45–3.3)
Colon/rectum 4.2 1.0 2.9 .70 (.17–2.8) 10.3 2.5 (1.0–6.3)
Stomach .80 1.0 4.9 6.2 (2.0–19) 1.8 2.3 (.30–18)
Lung 3.7 1.0 4.5 1.2 (.38–3.9) 4.2 1.1 (.27–4.6)
Kidney, bladder 1.3 1.0 2.6 2.0 (.46–8.4) 1.9 1.4 (.19–11)
Leukemias, etc. 1.9 1.0 4.8 2.6 (1.0–6.6) … …
Prostate 6.3 1.0 3.1 .48 (.066–3.5) 9.8 1.6 (.38–6.5)
Pancreas 1.1 1.0 1.6 1.5 (.20–11) 2.2 2.1 (.27–16)
Uterus 1.5 1.0 2.3 1.5 (.20–12) … …
All cancers, in:
Female relatives 26.3 1.0 66.3 3.6 (2.5–5.0) 32.1 1.3 (.69–2.3)
Male relatives 24.7 1.0 30.9 1.3 (.76–2.2) 38.9 1.7 (.97–3.1)
NOTE.—Cancers included are those reported in 291 relatives of cases with BRCA1 mutations, 160 relatives of cases with
BRCA2 mutations, and 4,378 relatives of cases with no mutations. Analysis of ovarian, breast, and uterine cancers was in
female relatives only; analysis of prostate cancer was in male relatives only; analysis of other cancers, as well as of all cancers
combined, was in relatives of both sexes.
a RRs and 95%CIs were obtained from proportional-hazards regression models, with relatives of cases not carryingmutations
as baseline; in the regression models, the cumulative incidence was obtained by subtracting, from unity, the estimated survival
(to age 80 years).
b An ellipsis (…) indicates that no cancers were reported among family members of cases.
increased risk of cancers at all sites that was seen among
males (RR 1.9 [95%CI 1.00–3.6]; penetrance 55%).
Discussion
Our study of 649 unselected cases of ovarian cancer, is
the largest population-based series to date and is com-
prehensively representative of all incident ovarian can-
cers, both borderline and invasive, arising in a defined
geographic area of North America. We did not restrict
probands to early-onset cases. Our study tested both for
mutations in BRCA1 and for mutations in BRCA2 and
obtained detailed family histories of all cases. Because
our study was population based, the family histories are
representative of those of all cases of ovarian can-
cer—and not of families selected for high occurrence of
cancer, as is observed in studies of subjects in genetic-
testing clinics.
Nevertheless, our overall case-participation rate
(63%) was a little lower than desired, and the 19%
nonparticipation due to death prior to subject contact
slightly increased the proportion of cases with border-
line versus invasive histology. It is possible that our en-
rolled subjects could therefore underrepresent those
cases of ovarian cancer that had worse prognoses, such
as cases occurring at a younger age or having poor-
prognosis histological types (e.g., clear cell and mucin-
ous). The age distribution of our cases (table 3), how-
ever, is similar to that seen in ovarian cancer in general
in the United States (Ries et al. 1994), although the
percentage of cases of age !50 years was slightly greater,
and the percentage of cases at age 160 years was slightly
smaller, than that in the United States. Our distribution
of histologies (clear cell 4.5%; mucinous 15%) is also
very similar to distributions in the United States and
Canada (Risch et al. 1996). Our sample of cases thus
appears to be highly representative of cases of ovarian
cancer in North America.
Another possible weakness in this study is that family-
history information was obtained by personal interview
and was not confirmed by either pathology report or
other medical records. Such information may be less
valid than confirmed cancer identifications, but errors
are likely to be nondifferential between carriers of mu-
tations and noncarriers and among carriers of the var-
ious types of mutations, tending to produce observed
associations shifted toward the null. We restricted our
penetrance analyses to use only information on first-
degree relatives, for whom the reported cancer histories
are likely to be the most accurate.
Finally, even though we tested 649 subjects, only 60
with mutations were identified, limiting the statistical
power for studying certain associations. In particular,
the numbers of families with cases carrying BRCA2mu-
tations and ovarian, colorectal, stomach, pancreatic, or
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prostate cancers in relatives were small; in most in-
stances, no more than one of these cancers occurred in
any given family, making our estimates of confidence
intervals and statistical significance reasonably valid. In
conclusion, because of the size and strengths of this
study, we believe that our results provide the most ac-
curate description of BRCA1 and BRCA2 associations
in ovarian cancer that thus far has been published.
In genetic screening of the 649 cancer cases, we found
that the hereditary proportion of invasive ovarian can-
cer in Ontario was 111%; for the large subgroup of
serous cancers, the frequency reached 16%. Our strat-
egy using PTT and DGGE, combined with specific as-
says for a number of founder mutations, was designed
to be reasonably rapid and inexpensive and, at the same
time, comprehensive. It is possible, however, that some
mutations could have been missed in this screen—and
that the hereditary fraction could thus be somewhat
higher, perhaps 10%–15% greater for BRCA1 and
20%–25% greater for BRCA2. The sensitivity of mu-
tation detection has been found to be similar for direct
sequencing compared with other standard methods
(Ford et al. 1998). As does sequencing, the testing strat-
egy employed here misses genomic rearrangements,
which are thought to account for !10% of BRCA1
mutations and for an even smaller fraction of BRCA2
mutations (Unger et al. 2000).
Previous estimates of the hereditary fraction of ovar-
ian cancer in general populations have typically been
less than ours. Takahashi et al. (1995) found germline
BRCA1mutations in 7 (6.1%) of 115women diagnosed
with invasive cancer in a multi-institutional U.S. hos-
pital–based pathology series. Matsushima et al. (1995)
found 4 cases (5.3%) with mutations among 76 women
with resected ovarian cancers, in a hospital series in
Japan. Stratton et al. (1997) identified BRCA1 muta-
tions in 13 (3.5%) of 374 women diagnosed with ovar-
ian tumors, both borderline and invasive, in a single
hospital in England. Rubin et al. (1998) found germline
BRCA1mutations in 10 (8.8%) of 113 cases of ovarian
cancer in a Philadelphia-hospital series; Van der Looij
et al. (2000) identified BRCA1 mutations in 10 (11%)
of 90 cases of ovarian cancer, in a hospital-based series
in Hungary; and Khoo et al. (2000) found BRCA1mu-
tations in 6 (11%) of 53 hospital cases in Hong Kong;
however, Janezic et al. (1999) found BRCA1mutations
in only 2 (1.9%) of 107 cases in a population-based
study in southern California. With regard to BRCA2,
Foster et al. (1996) observed germline BRCA2 muta-
tions in 2 (4%) of 50 cases of ovarian cancer, in a
combined sample from Australia, the United Kingdom,
and the United States; Takahashi et al. (1996) identified
mutations in 4 (3.1%) of 130 cases in their extended
pathology series, Van der Looij et al. (2000) none in
their hospital series, and Khoo et al. (2000) 1 (2.3%)
in their 43 hospital cases tested. In the Rubin et al.
(1998) study, only one BRCA2 mutation was observed
in the 113 cases, and this woman also carried a BRCA1
mutation. Rubin et al. (1998) concluded that the con-
tribution of BRCA2 to ovarian cancer is minimal, but
the sample sizes of studies to date have been small. In
our much larger study, BRCA2 mutations clearly ac-
count for an appreciable fraction of hereditary cases.
For both BRCA1 and BRCA2, it is likely that mu-
tation-frequency differences according to ethnic group
produce some of the observed differences between the
various studies. This is seen, in the Stratton et al. (1997)
report, in the low fraction of cases with BRCA1 mu-
tations, which is consistent with the low percentagewith
such mutations that is present among our cases of Brit-
ish Isles ancestry. The mutation fraction given by Strat-
ton et al. (1997) may be an underestimate, however,
because those authors did not look for the BRCA1 exon
13 6-kb duplication, which may be a founder mutation
in the population that they studied (The BRCA1 Exon
13 Duplication Study Group 2000). Our finding of
greater frequency of mutations among cases of ovarian
cancer that are of Italian and Indo-Pakistani extraction
than among British or mixed northern- or western-Eu-
ropean ethnicity is interesting and suggests that ethnic
composition needs further examination in population-
based studies of mutation frequency.
The importance of BRCA2 as an appreciable con-
tributor to hereditary ovarian cancer has not been well
recognized. This is largely because women with cancers
attributable to BRCA2 are not young and because an
appreciable number do not have strong family histories.
Our data show that BRCA2-associated ovarian cancer
occurs at the same ages as does sporadic invasive ovar-
ian cancer. Although our numbers are somewhat small,
the majority of hereditary cancers in women diagnosed
at age 160 years were in BRCA2 carriers. This finding,
in our general-population series, is similar to the pre-
dominance, in Ashkenazi Jews, of BRCA2 mutations
among ovarian cancer–mutation carriers who are age
160 years (Boyd et al. 2000; Moslehi et al. 2000). As
well, these observations are consistent with the Breast
Cancer Linkage Consortium (Ford et al. 1995) report
based on linkage using markers on chromosome 13,
which estimated the cumulative incidence of ovarian
cancer among BRCA2 carriers to be 0.4% by age 50
years but 27% by age 70 years. Themajority ofBRCA2-
associated cancers are thus expected to appear at age
50–70 years, and this is consistent with our observations
(table 3).
On the other hand, ovarian cancers occurring among
carriers of BRCA1 mutations were diagnosed, on av-
erage, ∼4–5 years earlier than those among women not
found to have mutations and ∼7 years earlier than spo-
radic invasive ovarian cancer. BRCA1-associated cases
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typically occur during a patient’s 40s and 50s, with
!10% being diagnosed at age !40 years. Other studies
have also shown only a small percentage of cases oc-
curring at age !40 years (Stratton et al. 1999; Boyd et
al. 2000).
Histology of cases is also useful in distinguishing
whether a mutation is likely to be present. Elsewhere,
we have suggested that mucinous ovarian cancer is eti-
ologically distinct from nonmucinous cancer (Risch et
al. 1996), and this observation appears to carry over to
the presence of BRCA1 or BRCA2 mutations. In the
present study, we observed no mutations among 44
women with invasive mucinous tumors. The study by
Stratton et al. (1997) apparently found one BRCA1
mutation among 52 cases with mucinous tumors, and
a study in Scandinavia (Jo´hannsson et al. 1997) found
no women with mucinous tumors among 15 cases with
BRCA1mutations. In the Gynecologic OncologyGroup
case series, no women with mucinous tumors were
found among either six cases with BRCA1 mutations
or four cases with BRCA2 mutations (Takahashi et al.
1995, 1996); nor were any found in two studies of
nearly 100 Ashkenazi Jewish women with BRCA1-as-
sociated ovarian cancer (Muto et al. 1996; Boyd et al.
2000). Finally, a collected series of 68 Ashkenazi Jewish
women with ovarian cancer and carrying germline
BRCA1 or BRCA2 mutations apparently found one
case with a mucinous tumor (Moslehi et al. 2000). In
the present study, mutations also were not seen among
cases of ovarian cancer of borderline invasiveness (low
malignant potential), and this is consistent with other
reports as well (Gotlieb et al. 1998).
Because of the population-based sampling of our case
series and the complete reporting of cancer histories
among first-degree relatives, we were able to estimate
the lifetime penetrance of breast cancer and of ovarian
cancer associated with carriage of germline mutations.
The lifetime penetrance of breast cancer among carriers
of BRCA1 mutations, 68%, is within the 45%–74%
range that has been estimated elsewhere (Whittemore
et al. 1997; Antoniou et al. 2000); also, the lifetime
penetrance of ovarian cancer among carriers of BRCA1
mutations, 36%, is within the 28%–66% range estab-
lished elsewhere (Whittemore et al. 1997; Antoniou et
al. 2000). However, these ranges are wide. The estimates
by Whittemore et al. (1997) were made on the basis of
population-based case-control studies that had no mu-
tation testing and that therefore required that assump-
tions about the carriage of mutations be based on family
history. The estimates by Antoniou et al. (2000) were
made on the basis of modeling of both an unselected
case series and a set of highly affected families. Our
estimated penetrance values are based solely on a large
population series of unselected cases—and, therefore,
of families unselected for cancer incidence. It is never-
theless possible that the probands that we studied could
have underreported the existence of cancers among their
first-degree relatives; however, the cumulative inci-
dences of ovarian and breast cancer among noncarrier-
case relatives—2.5% and 9.9%, respectively—are sim-
ilar to general-population lifetime risks and suggest that
the underreporting of affected relatives is not an ap-
preciable issue here. Our penetrance estimates are there-
fore likely to be reasonably valid.
An interesting new finding in the present study is the
trend of breast-cancer penetrance increasing according
to more-downstream mutation location within the
BRCA1 coding sequence. Shattuck-Eidens et al. (1995)
did not find any apparent clustering of breast cancers
in families of carriers by mutation location in the
BRCA1 coding sequence. Studies of Ashkenazi Jews
show that the 5382insC mutation may have a breast-
cancer penetrance similar to that of the 185delAG mu-
tation (Levy-Lahad et al. 1997; Moslehi et al. 2000);
however, if, as has been suggested, the prevalence of the
5382insC mutation in the general Ashkenazi commu-
nity proves to be only ∼10% of that of the 185delAG
mutation (Tonin et al. 1996), then its penetrance for
breast cancer could be appreciably greater. Gayther et
al. (1995) found a significant correlation between the
location of the BRCA1 mutation in the gene and the
breast:ovary ratio of cancer incidence in the family, with
3′-third mutations associated with a lower proportion
of ovarian cancer. In a series with ovarian cancer uni-
formly present (as in the present study), this would re-
sult in an excess of breast cancer cases in families with
mutations in the 3′ third, as we have found. Whether
there should also be a relative deficit of breast cancer
in families with 5′ mutations is unclear; only two breast
cancers were reported among 42 female first-degree rel-
atives of the 12 cases with 5′ BRCA1 mutations, in-
cluding the 5 with the 185delAG mutation.
It is also interesting that overall we did not find an
excess of breast cancer among family members of cases
carrying BRCA2 mutations. This appears to be a result
of our study sampling, in which at least one case of
ovarian cancer (the proband) exists in each family, giv-
ing a moderately high proportion (62%) of BRCA2
mutations within the OCCR. By considering OCCR
and non-OCCR BRCA2 mutations separately, we did
see a significant excess of breast cancer in families with
non-OCCR mutations. In a large set of families with
breast-ovarian cancer and germline BRCA2 mutations,
Thompson and Easton (2001) have recently also found
only non-OCCR mutations to be associated with in-
creased risk of breast cancer.
Our finding that an elevated risk of colorectal, stom-
ach, pancreatic, and prostate cancer is associated spe-
cifically with OCCR BRCA2 mutations is also new.
Although, in some studies (e.g., Lehrer et al. 1998; Sin-
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clair et al. 2000), prostate cancer has not been associ-
ated with BRCA2mutations, the Breast Cancer Linkage
Consortium (1999) analysis of 173 families with
BRCA2 mutations shows that prostate, as well as co-
lorectal, stomach, and pancreatic cancer, seems to be
more frequent among carriers of BRCA2 mutations
than among noncarriers. Whether the increase in risk
of cancers at these sites is due essentially to OCCR
mutations remains to be seen. Thompson and Easton
(2001) have observed greater increased risk of prostate
cancer with non-OCCR mutations than with OCCR
mutations. Phelan et al. (1996) did find a few families
with non-OCCR BRCA2 mutations and cancers of
these various sites. Overall, the issue does not appear
to have been systematically studied. Our finding of in-
creased cancer risks specifically with OCCR muta-
tions is probably not attributable to the BRCA2-screen-
ing methods that we used, since the OCCR as
considered here—that is, nucleotides 4075–6503, inclu-
sive (Thompson and Easton 2001)—comprises only
40% of the screened coding length of exons 10 and 11.
Indeed, in 8 (38%) of our 21 cases with BRCA2 mu-
tations, the mutations were outside the OCCR, and this
fraction is very similar to the 41% that Thompson and
Easton (2001) have seen among 119 cases of ovarian
cancer with BRCA2 mutations.
There are a number of potential clinical recommen-
dations that can be inferred from our results. Risk-fac-
tor analysis has been used to predict the presence of
BRCA1mutation in high-risk subjects (Shattuck-Eidens
et al. 1997). This method provides a suitable threshold
on the basis of which genetic testing can be offered, but
it cannot reassure individual women that, if tested, they
would not be found to be carrying mutations. The same
may be said for age at diagnosis, family history, or eth-
nicity, in counseling cases of ovarian cancer. However,
only ovarian cancers of invasive nonmucinous histology
are likely to be associated with BRCA1 or BRCA2mu-
tations. The frequency of mutations in general North
American populations thus suggests that it is reasonable
to offer genetic testing to all women with invasive non-
mucinous ovarian cancer. It would seem not to be pru-
dent to exclude patients from screening because they
lack a family history. In our study, 33 of 60 mutations
would have been missed if we had restricted screening
to women with at least one affected first-degree relative.
In contrast, none of the mutations would have been
missed if our efforts had been limited to the subgroup
of invasive nonmucinous tumors, and we would have
reduced the extent of screening by 33%. It also appears
worthwhile to test all women with invasive nonmuci-
nous ovarian cancer for the three common Ashkenazi
Jewish founder mutations, since they occur not infre-
quently in other ethnic groups. In addition, testing
should include examination of the BRCA1 exon 13 6-
kb duplication mutation, which is missed by standard
assay methods, including direct sequencing (Puget et al.
1999).
If confirmed in future studies, the finding that pene-
trance of breast cancer increases with more-distal mu-
tation location along the BRCA1 coding sequence may
be important for genetic counseling. If, in the general
population, the risk of breast cancer proves not to be
appreciably elevated withmutations in the proximal end
of the gene, then it is possible that women carrying such
mutations may be able to avoid disfiguring surgery. Our
study did not find a BRCA1-location effect on pene-
trance of ovarian cancer, but the number of cases among
family members of carriers was small. The BRCA1-mu-
tation penetrance for ovarian cancer appears to be suf-
ficiently great that prophylactic oophorectomy or other
prevention strategies are warranted. Finally, for cancers
at all sites combined, if future studies show the pene-
trance of BRCA2 mutations, particularly OCCR mu-
tations, is high in male carriers, as it is in female carriers,
then males will need to be included in genetic-testing
programs whenever the presence of a BRCA2mutation
is suspected.
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